PAREXEL, ASAN Medical Center Forge Korean Alliance

PAREXEL International Corp. has entered into an agreement with Seoul-based ASAN Medical Center (AMC). The alliance offers regional and international sponsors with access to quality clinical trial services throughout Asia, with a focus on early phase development.

“Through our collaboration with AMC we look forward to helping our clients take advantage of opportunities to support their Korea-based development and commercialization programs to benefit patients in Korea, throughout Asia, and around the world,” said Mark A. Goldberg, M.D., chief operating officer, PAREXEL International. “PAREXEL provides clients with patient access in key therapeutic areas for early phase development through our early phase units and global alliance network. Our relationship with the AMC affords us the opportunity to further extend this capability into Asia. With AMC’s leadership in clinical trials, in-depth expertise, state-of-the art facilities, and a renowned network of hospitals, we believe our alliance will offer unique advantages to the Korean biopharmaceutical industry.”

“ASAN Medical Center is pleased to work with PAREXEL to help advance our research activities and develop meaningful innovations that contribute to health and longevity of patients in Korea and throughout Asia,” said Seong-Wook Park, M.D. Ph.D, president and chief executive officer, AMC. “We look forward to collaborating with PAREXEL through our department of Clinical Pharmacology and Therapeutics to promote, facilitate, and enhance the development and use of novel pharmacotherapeutics.”